Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris

Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00202566

Acronym

ASSOCIATE

Enrollment

750

Registered

2005-09-20

Start date

2005-06-30

Completion date

2007-10-31

Last updated

2018-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris

Brief summary

To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris

Interventions

DRUGIvabradine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Chronic stable angina pectoris * Documented coronary artery disease * Previous treatment with atenolol or other beta-blocker agent * Exercise tolerance test positivity and stability

Exclusion criteria

* Heart rate \< 60 bpm * Congestive heart failure

Design outcomes

Primary

Measure	Time frame
Improvement between baseline and end of treatment of the treadmill exercise tolerance test	—

Secondary

Measure	Time frame
Rate pressure product	—
Clinical evaluation	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026